Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy

[1]  Ching-Yu Cheng,et al.  Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients. , 2006, Investigative ophthalmology & visual science.

[2]  B. Rosner,et al.  Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. , 2007, JAMA.

[3]  A. Luff,et al.  An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment , 2008, Eye.

[4]  Verteporfin Roundtable Participants.  GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES , 2002, Retina.

[5]  M. Blumenkranz,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. , 2002, Archives of ophthalmology.

[6]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Edwards,et al.  Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.

[8]  J. Vander.  Complement Factor H Increases Risk for Atrophic Age-Related Macular Degeneration , 2007 .

[9]  N. Camp,et al.  A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration , 2006, Science.

[10]  J. Gilbert,et al.  Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.

[11]  W. März,et al.  Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. , 2007, Ophthalmology.

[12]  N. Bressler,et al.  New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. , 2006, Acta ophthalmologica Scandinavica.

[13]  J W Berger,et al.  Age-related macular degeneration. , 2000, The New England journal of medicine.

[14]  Chi Pui Pang,et al.  HTRA1 promoter polymorphism in wet age-related macular degeneration. , 2007, Science.

[15]  N. Bressler.  GUIDELINES FOR USING VERTEPORFIN (VISUDYNE) IN PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES: UPDATE , 2005, Retina.

[16]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.

[17]  ウィークス，ダニエル・イー,et al.  Susceptibility gene for age-related macular degeneration on chromosome 10q26 (ARM) , 2006 .

[18]  S. Fisher,et al.  Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk , 2005 .

[19]  M. Brantley,et al.  Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration. , 2007, American journal of ophthalmology.

[20]  E. Souied,et al.  Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. , 2005, Molecular vision.